Merck Selects Dendrite's Field Sales Channel Management Application For National Deployment; PDA-Driven SFA Application Custom-Designed For In-House Sales Management System

Business Wire, Feb 18, 2003

Business Editors

MORRISTOWN, N.J.--(BUSINESS WIRE)--Feb. 18, 2003

Dendrite International, Inc. (NASDAQ: DRTE) today announced that it has signed a comprehensive software and maintenance service contract with Merck & Co., Inc., under which the pharmaceutical company will begin full deployment of a handheld field sales channel management application custom-designed and programmed by Dendrite for its entire U.S. sales force.

Dendrite's fourth quarter earnings call on January 29 included an anonymous discussion of this agreement.

"Our partnership with Merck is the result of more than a year-and-a-half of extremely close collaboration to design, configure, and implement a sales force tool to meet Merck's specific requirements," said Dendrite Group President Mike Atieh.

Dendrite's application will enable Merck's sales force to use handheld devices, increasingly popular with mobile field-based representatives, to, among other things, record and view customer information. Home office (headquarters-based) personnel will have the capability of sending sales data directly to representatives' PDAs for viewing and subsequent follow-up action.

About Dendrite

Dendrite develops and delivers solutions that increase value in sales, marketing, and clinical processes for life sciences clients. For more information, visit www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

The foregoing contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The statements may be identified by such forward-looking terminology as "expect," "believe," "may," "will," "intend," "plan," and similar statements or variations. All "outlook" information constitutes forward-looking statements. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve certain significant risks and uncertainties, including those which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for our products, our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on major customers; changes in demand for our products and services attributable to the current weakness in the economy; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; acquisitions; events which may affect the U.S. and world economies; our ability to manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; the potential for hostilities in the Middle East and Asia and the resulting impact on our business and the business and needs of our customers; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be considered are included in the Company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The Company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.